Rafoxanide Induces Immunogenic Death of Colorectal Cancer Cells.
Ontology highlight
ABSTRACT: Colorectal cancer (CRC) is a major cause of cancer-related death in the world. Emerging evidence suggests that the clinical success of conventional chemotherapy does not merely rely on cell toxicity, but also results from the restoration of tumor immune surveillance. Anti-tumor immune response can be primed by immunogenic cell death (ICD), a form of apoptosis associated with endoplasmic reticulum stress (ERS) induction and the expression/release of specific damage-associated molecular patterns (DAMPs). Unfortunately, a limited number of ICD inducers have been identified so far. The anti-helmintic drug rafoxanide has recently showed anti-tumor activity in different cancer types, including CRC. As such latter effects relied on ERS activation, we here investigated whether rafoxanide could pro
SUBMITTER: Di Grazia A
PROVIDER: S-EPMC7281008 | biostudies-literature | 2020 May
REPOSITORIES: biostudies-literature
ACCESS DATA